Rani Therapeutics启动RT-114（一种口服Ranipill胶囊，含有GLP-1/GLP-2双重激动剂PG-102）治疗肥胖的I期试验

2026-01-08 20:14

PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen Co., Ltd. ("ProGen"). ProGen recently announced preclinical and clinical data, at the 2025 European Association for the Study of Diabetes (EASD) meeting, demonstrating glucose-lowering effects and meaningful early weight-loss signals by PG-102, reinforcing its potential as a next-generation metabolic therapy.
In preclinical testing of RT-114 in animal models, the RaniPill® delivered PG-102 orally with bioavailability, pharmacokinetics, and weight loss comparable to subcutaneous (SC) injection.